Establishment of a Decision Aid Tool for Asymptomatic Small Leiomyoma and Analysis of Influencing Factors for Clinical Decision-making Using HIFU
1 other identifier
observational
120
1 country
1
Brief Summary
With the younger patients diagnosed with asymptomatic leiomyoma, delay in the reproductive age of women, the advancement of medical technology, and the rapid development of treatment methods, there are many choices between gynecologists, gynecologists and patients because of experience and knowledge. It is not easy to make the most favorable choice for patients. This study is mainly led by a committee composed of designers, doctors, nurses and patients, and based on clinical guidelines and evidence-based medicine. Co-operating with patients with asymptomatic small leiomyoma, we want to find the influencing factors of clinical decision-making, and to establish a patient decision aid tool. We use prospective trial to verify that the use of this tool can improve patients' decision-making efficacy and further improve patient-reported outcomes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Aug 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 9, 2022
CompletedFirst Posted
Study publicly available on registry
August 12, 2022
CompletedStudy Start
First participant enrolled
August 31, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
August 31, 2027
ExpectedAugust 12, 2022
August 1, 2022
2 years
August 9, 2022
August 10, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Patient satisfaction after using PDAs
The patients in PDAs will undertake the treatment by PDAs. And we will collect the satisfaction after 12 months.
6-12 months
Study Arms (2)
communication without PADs
We use traditional communication ways to discuss the conditions with patients.
communication with PADs
The committee, composed of designers, doctors, nurses and patients, bases on guidelines and evidence-based medicine to make a tool. And we use this tool to discuss the conditions with patients.
Interventions
Patient Decision Aids (PDAs) are an important way to facilitate making decision by patients, helping patients make specific and prudent choices by providing information about treatment options and corresponding outcomes, including benefits and risks, related to their health status. The purpose of PDAs is to encourage patients to participate in decision-making. It makes it easier for patients and doctors to discuss treatment options. It effectively promotes communication between patients and doctors. It can help patients combine their own needs and professional advice to make better, more individualized diagnosis and treatment options.
Eligibility Criteria
18-55 years old woman diagnosed with uterine fibroids and without clinical symptoms
You may qualify if:
- Diagnosis of leiomyoma: patients with leiomyoma diagnosed by imaging examinations (ultrasound and MRI) have no clinical symptoms;
- Female with age in 18-55 years old;
- The maximum diameter of a single leiomyoma is less than 5m, and the number does not exceed 10 by MRI;
- No contraindications for sedation and analgesia;
- Patients and their families agree to join this study, and can follow up on time.
You may not qualify if:
- History of myomectomy, including transabdominal, laparoscopic, hysteroscopy, etc.;
- History of connective tissue diseases or radiotherapy, especially abdominal radiotherapy;
- With pregnancy, acute inflammation of the reproductive tract, or other gynecological benign and malignant diseases such as endometriosis and ovarian tumors;
- The maximum diameter of leiomyoma is greater than or equal to 5cm;
- Suspected malignant tumor, such as sarcoma;
- Those with language communication barriers and unable to cooperate with sedative and analgesic programs;
- Abdominal scarring, when diagnosed by ultrasound transabdominal scan, has obvious sound attenuation (more than 10mm range).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shenzhen Maternal and Child Health Hospital
Shenzhen, Guangdong, 518000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
August 9, 2022
First Posted
August 12, 2022
Study Start
August 31, 2022
Primary Completion
August 31, 2024
Study Completion (Estimated)
August 31, 2027
Last Updated
August 12, 2022
Record last verified: 2022-08
Data Sharing
- IPD Sharing
- Will not share